AARD

Aardvark Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 3/10
Aardvark Therapeutics sales and earnings growth
AARD Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 39.55%
  • FCF Y/Y↓ -125.45%
Aardvark Therapeutics gross and profit margin trends
AARD Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Aardvark Therapeutics net debt vs free cash flow
AARD Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Aardvark Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks